Pharmaceutical - Antibiotics and Infectious diseases


Popular Filters

126 to 150 of 226 results

Hikma licenses Vibativ from Theravance for MENA region


Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) says it has signed an exclusive commercialization…

Antibiotics and Infectious diseasesHikma PharmaceuticalsLicensingPharmaceuticalRest of the WorldTheravanceVibativ

US FDA puts clinical hold on Achillion's sovaprevir on safety concerns


USA-based Achillion Pharmaceuticals (Nasdaq: ACHN) announced yesterday (July 1) that the US Food and…

Achillion PharmaceuticalsAntibiotics and Infectious diseasesatazanivirPharmaceuticalRegulationsovaprevir

India must address worrying stock out of tuberculosis drugs, says MSF


The Indian government must urgently address the persistent issues and almost routine delays of procuring…

Antibiotics and Infectious diseasesAsia-PacificHealthcareMarkets & MarketingPharmaceuticalPolitics

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds


Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians


More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France,…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceutical

Ferrer's Ozenoxacin shows superiority in Ph III impetigo trial


Privately-held Spanish drugmaker Ferrer Internacional says that it has successfully completed a Phase…

Antibiotics and Infectious diseasesDermatologicalsFerrer InternacionalLicensingOzenoxacinPharmaceuticalResearch

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products


UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

Merck & Co returns antifungal MK-3118 rights to Scynexis


US venture capital backed drug developer Scynexis says that pharma giant Merck & Co has decided to return…

Antibiotics and Infectious diseasesLicensingMerck & CoMK-3118PharmaceuticalScynexis

Grifols gains global rights to Aradigm's Pulmaquin


Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's…

Antibiotics and Infectious diseasesAradigmCiprofloxacinGrifolsLicensingMergers & AcquisitionsPharmaceuticalPulmaquinRespiratory and Pulmonary

GlaxoSmithKline gets $200 million BARDA award to develop new antibiotics


UK pharma giant GlaxoSmithKline (LSE: GSK) and the Biomedical Advanced Research and Development Authority…

Antibiotics and Infectious diseasesFinancialGlaxoSmithKlinePharmaceuticalResearch

Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal


Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk…

Antibiotics and Infectious diseasesGenericsMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalXellia Pharmaceuticals

Infectious disease treatments market driven by growth in middle-income to low-income countries


The infectious disease treatments market increased at a compound annual growth rate (CAGR) of 6.9% between…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalVaccines

Cempra out-licenses solithromycin to Toyama Chemical in Japan


USA-based clinical-stage antibiotics developer Cempra (Nasdaq: CEMP) has signed an exclusive license…

Antibiotics and Infectious diseasesAsia-PacificCempraLicensingPharmaceuticalsolithromycinToyama

Shire's ADHA drug Elvanse accepted for NHS use in Scotland; UK guidance on fidaxomicin


Ireland-headquartered Shire plc (LSE: SHP) said yesterday (May 13) that its single-daily dose long-acting…

Antibiotics and Infectious diseasesAstellas PharmaDificlirElvanseEuropefidaxomicinNeurologicalPharmaceuticalRegulationShire

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone


US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

Soligenix and Intrexon collaborate on Melioidosis therapy development


US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection


In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirfidaxomicinPharmaceuticalPricingRegulation

New European anti-infectives company, Allecra Therapeutics, created


The creation of Allecra Therapeutics, a new company joining the established European BioValley Life Sciences…

Allecra TherapeuticsAntibiotics and Infectious diseasesFinancialOrchid Chemicals & PharmaceuticalsPharmaceuticalResearch

Breakthrough status for Pfizer's palbociclib; Merck & Co Noxafil NDA accepted


Global pharma behemoth Pfizer (NYSE: PFE) is the latest to gain a "Breakthrough Therapy" designation…

Antibiotics and Infectious diseasesMerck & CoNorth AmericaNoxafilOncologypalbociclibPfizerPharmaceuticalRegulation

126 to 150 of 226 results

Back to top